Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Bozdağ, Sinem Civriz; Seval, Güldane Cengiz; Hindilerden, İpek Yönal; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Kaynar, Lale Aydın; Toprak, Selami Koçak; Goksoy, Hasan Sami; Aydın, Berrin Balık; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Demi̇rci̇oğlu, Si̇nan; İnce, İdris; Yılmaz, Ümit; Küçükdiler, Hilal Eroğlu; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yasa Gul; Baş, Volkan; Özkalemkaş, Fahir; Teke, Hava Üsküdar; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli̇, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yeğin, Zeynep Arzu; Yüksel, Meltem Kurt; Sadri, Sogol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Sevindik, Omur Gokmen; Akyay, Arzu; Özcan, Muhıt; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Küçükkaya, Reyhan Diz; Özsan, Güner Hayri

doi:10.4274/tjh.galenos.2021.2021.0287

Cited by 7 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with hematological malignancies have a high rate of mortality with SARS-CoV-2 infection. In a study with over 300 hematology patients (70% myeloma, acute leukemia, and active lymphoma), the mortality was 26%, which is markedly higher than our findings in CML patients ( 13 ). The same study showed a mortality of 83% for patients with critical illness.…”

Section: Discussioncontrasting

confidence: 81%

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

Ali,

Al-Sadi,

Al-maharmeh

et al. 2024

Front. Med.

View full text Add to dashboard Cite

IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus causing the coronavirus disease of 2019. The disease has caused millions of deaths since the first pandemic at the end of 2019. Immunocompromised individuals are more likely to develop severe infections. Numerous mutations had developed in SARS-CoV-2, resulting in strains (Alfa Beta Delta Omicron) with varying degrees of virulence disease severity. In CML (chronic myeloid leukemia) patients, there is a lot of controversy regarding the effect of the treatment on the patient outcome. Some reports suggested potential better outcomes among patients with CML, likely due to the use of TKI; other reports showed no significant effects. Additionally, it is unknown how much protection immunization provides for cancer patients.MethodIn accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, we conducted a systematic review. Retrospective, prospective studies, reviews, case series, and case reports of chronic myeloid leukemia patients aged above 18 years who had SARS-CoV-2 infection were included. English literature was screened using PubMed, SCOPUS, and Google Scholar. Search terms include chronic myeloid leukemia, chronic myelogenous leukemia, and SARS-CoV-2 and Coronavirus disease 2019 (COVID-19). We searched the reference lists of the included studies for any new articles. The search included all articles published up to April 20, 2023. The review is registered in PROSPERO (registration number CRD42022326674).ResultsWe reviewed 33 articles of available published literature up to April 2023 and collected data from a total of 682 CML patients with COVID-19. Most patients were in the chronic phase, seven were in the accelerated phase, and eight were in the blast phase. Disease severity was classified according to WHO criteria. Mortality was seen in 45 patients, and there were no reports of thrombotic events. Two hundred seventy-seven patients were in the era before vaccination; among them, eight were in the intensive care unit (ICU), and mortality was 30 (11%). There were 405 patients after the era of vaccination; among them, death was reported in 15 (4%) patients and ICU in 13 patients.Limitations and conclusionThe major limitation of this review is the lack of details about the use or hold of TKIs during SARS-CoV-2 infection. Additionally, after the appearance of the different variants of the SARS-CoV-2 virus, few studies mentioned the variant of the virus, which makes it difficult to compare the outcome of the other variants of the SARS-CoV-2 virus in patients with CML. Despite the limitations of the study, CML patients with COVID-19 have no significant increase in mortality compared to other hematological malignancy. Hematological cancers are associated with an increased risk of thrombosis, which is expected to increase in patients with COVID-19. However, patient with CML has not been reported to have a significant increase in thrombosis risk. The available data indicates that COVID-19’s effect on patients with chronic myeloid leukemia (CML) still needs to be better understood due to the limited data.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php? RecordID:326674.

show abstract

Section: Discussioncontrasting

confidence: 81%

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

Ali,

Al-Sadi,

Al-maharmeh

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

“…The most frequent symptoms were fever, weakness, cough, and dyspnea. 7 , 13 , 20 , 22 , 27 We detected significant differences in the incidences of the admitting symptoms between the survivors and non-survivors. Fever, fatigue, dyspnea, irritability/confusion, gastrointestinal complaints, and chest pain were more frequently seen in the non-survivors.…”

Section: Discussionmentioning

confidence: 75%

Impact of Covid-19 on Outcomes of Patients With Hematologic Malignancies: A Multi-Center, Retrospective Study

Açar

Güner

et al. 2022

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause mortality. Methods: A multi-center, observational retrospective analysis of patients with hematologic malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study. Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematologic malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). There were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Cardiac comorbidities, (p=0.016), cytotoxic chemotherapy (p=0.024), low lymphocyte percentage (p=0.025), thrombocytopenia (p<0.0001), and high CRP values (p=0.017) were the independent risk factors for the prediction of mortality. Conclusions: In patients with hematologic malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Cardiac diseases, cytotoxic chemotherapy, lymphopenia, thrombocytopenia, and high CRP are the independent risk factors for mortality in hematologic malignancy patients with COVID-19. Keywords: Covid; Hematologic Malignancy; Cytotoxic chemotherapy.

show abstract

“…Vijenthira et al 6 ) reported a higher risk of mortality in hospitalized patients with HD (39%) compared to that in all HD patients (34%), whereas the in-hospital mortality in patients aged >60 years (47%) was significantly higher. A cohort including outpatients with HD and COVID-19 reported a mortality rate of only 26.5% 22 ) . Thus, physicians should take care in treating patients with HD, especially those who are or may be hospitalized during the COVID-19, pandemic to limit their risk of exposure to COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of coronavirus disease 2019 and seasonal influenza in patients with hematological disorders: a retrospective study

et al. 2022

View full text Add to dashboard Cite

Objective: The differences in clinical outcomes in hospitalized patients with hematological disorders (HD) who developed either coronavirus disease 2019 or seasonal influenza (SI) are not fully understood. To examine these differences, we retrospectively analyzed the baseline characteristics and clinical outcomes of hospitalized patients with HD admitted from 2016 to 2021. Patients and Methods: Patients with HD who developed COVID-19 (in the past 1 year) (n=21) or SI (in the past 5 years) (n=23) in the Department of Hematology/Oncology, Asahikawa Kosei General Hospital were evaluated. Results:The median ages of the patients with HD with either COVID-19 or SI were 80 and 68 years, respectively (P=0.03). The groups showed no significant differences in sex ratio, body mass index, or Eastern Cooperative Oncology Group performance status. In the COVID-19 and SI groups, the most common primary diseases were diffuse large B-cell lymphoma (43%) and multiple myeloma (39%), respectively. The median numbers of days of oxygen administration (8 vs. 0 days), quarantine (25 vs. 6 days), and hospitalization (72 vs. 21 days) were significantly higher in HD patients with COVID-19 than those in HD patients with SI (all P<0.001). The overall 90-day survival of patients with HD and COVID-19 was significantly shorter than that of patients with HD and SI (P=0.019). Moreover, patients with HD and COVID-19 had a higher risk of in-hospital mortality (43% vs. 9%; odds ratio, 7.50; 95% confidence interval, 1.26-82.4; P=0.01) compared to patients with HD and SI. Conclusion: Patients with HD and COVID-19 required longer periods of in-hospital medical and showed poorer survival than those with SI. During the COVID-19 pandemic, hematologists should closely monitor the condition of patients with COVID-19 to closely monitor their condition to prevent deaths.

show abstract

Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Cited by 7 publications

References 28 publications

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

SARS-CoV-2 and chronic myeloid leukemia: a systematic review

Impact of Covid-19 on Outcomes of Patients With Hematologic Malignancies: A Multi-Center, Retrospective Study

Clinical outcomes of coronavirus disease 2019 and seasonal influenza in patients with hematological disorders: a retrospective study

Contact Info

Product

Resources

About